Lexicon Pharmaceuticals LXRX Stock
Lexicon Pharmaceuticals Price Chart
Lexicon Pharmaceuticals LXRX Financial and Trading Overview
| Lexicon Pharmaceuticals stock price | 2.2 USD |
| Previous Close | 2.22 USD |
| Open | 2.2 USD |
| Bid | 1.89 USD x 100 |
| Ask | 2.52 USD x 100 |
| Day's Range | 2.14 - 2.22 USD |
| 52 Week Range | 1 - 2.68 USD |
| Volume | 1.68M USD |
| Avg. Volume | 3.25M USD |
| Market Cap | 963.91M USD |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.07 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.77 USD |
LXRX Valuation Measures
| Enterprise Value | 850.96M USD |
| Trailing P/E | N/A |
| Forward P/E | -10.519683 |
| PEG Ratio (5 yr expected) | -13.77 |
| Price/Sales (ttm) | 13.840675 |
| Price/Book (mrq) | 4.5302715 |
| Enterprise Value/Revenue | 12.219 |
| Enterprise Value/EBITDA | -35.946 |
Trading Information
Lexicon Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.05 |
| 52-Week Change | 88.13% |
| S&P500 52-Week Change | 20.84% |
| 52 Week High | 2.68 USD |
| 52 Week Low | 1 USD |
| 50-Day Moving Average | 2.08 USD |
| 200-Day Moving Average | 1.61 USD |
LXRX Share Statistics
| Avg. Volume (3 month) | 3.25M USD |
| Avg. Daily Volume (10-Days) | 6.91M USD |
| Shares Outstanding | 444.2M |
| Float | 262.53M |
| Short Ratio | 7.02 |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 78.52% |
| Shares Short | 30.78M |
| Short % of Float | 13.08% |
| Short % of Shares Outstanding | 6.92% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:7 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -37.46% |
| Operating Margin (ttm) | -4.71% |
| Gross Margin | 94.12% |
| EBITDA Margin | -33.99% |
Management Effectiveness
| Return on Assets (ttm) | -5.34% |
| Return on Equity (ttm) | -16.010% |
Income Statement
| Revenue (ttm) | 69.64M USD |
| Revenue Per Share (ttm) | 0.19 USD |
| Quarterly Revenue Growth (yoy) | 1572.09% |
| Gross Profit (ttm) | 65.55M USD |
| EBITDA | -23673000 USD |
| Net Income Avi to Common (ttm) | -26089000 USD |
| Diluted EPS (ttm) | -0.07 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 170.66M USD |
| Total Cash Per Share (mrq) | 0.38 USD |
| Total Debt (mrq) | 57.71M USD |
| Total Debt/Equity (mrq) | 28.45 USD |
| Current Ratio (mrq) | 18.795 |
| Book Value Per Share (mrq) | 0.479 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -38803000 USD |
| Levered Free Cash Flow (ttm) | -28858250 USD |
Profile of Lexicon Pharmaceuticals
| Country | United States |
| State | TX |
| City | The Woodlands |
| Address | 2445 Technology Forest Boulevard |
| ZIP | 77381 |
| Phone | 281 863 3000 |
| Website | https://www.lexpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 81 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Q&A For Lexicon Pharmaceuticals Stock
What is a current LXRX stock price?
Lexicon Pharmaceuticals LXRX stock price today per share is 2.2 USD.
How to purchase Lexicon Pharmaceuticals stock?
You can buy LXRX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lexicon Pharmaceuticals?
The stock symbol or ticker of Lexicon Pharmaceuticals is LXRX.
Which industry does the Lexicon Pharmaceuticals company belong to?
The Lexicon Pharmaceuticals industry is Biotechnology.
How many shares does Lexicon Pharmaceuticals have in circulation?
The max supply of Lexicon Pharmaceuticals shares is 444.2M.
What is Lexicon Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Lexicon Pharmaceuticals PE Ratio is now.
What was Lexicon Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Lexicon Pharmaceuticals EPS is -0.07 USD over the trailing 12 months.
Which sector does the Lexicon Pharmaceuticals company belong to?
The Lexicon Pharmaceuticals sector is Healthcare.
Lexicon Pharmaceuticals LXRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26269.23 USD — |
+0.62
|
6.33B USD — | 26041.13 USD — | 26316.81 USD — | — - | 6.33B USD — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7161.62 USD — |
+0.7
|
— — | 7044.78 USD — | 7163.12 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12896.68 USD — |
+0.63
|
— — | 12785.35 USD — | 12920.04 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6562.03 USD — |
+0.7
|
— — | 6454.97 USD — | 6563.4 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1251.97 USD — |
+0.86
|
— — | 1233.72 USD — | 1252.49 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32406.63 USD — |
+0.62
|
— — | 32125.24 USD — | 32465.34 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}